Skip to content
2000
Volume 15, Issue 2
  • ISSN: 1573-3947
  • E-ISSN: 1875-6301

Abstract

In recent, curiosity is at the forefront to understand the complexity of cancer driven by genetic, molecular and epigenetic programming due to life style, environmental pressure and metabolite adaptations. On the other hand, complex and heterogeneous nature of cancer is linked to the metabolic and molecular landscape of diabetic complications. This Letter to editor connects the dots and highlights the need to view cancer beyond the mirror of genetic and epigenetic aberration as metabolic disturbances. In this commentary, the author highlights the major contributions from two elegant papers from Cha et al. (2018) and Wu et al. (2018) by delineating molecular pathways that lead to the potential use of anti-diabetic drug metformin and other potential repurposing drugs towards cancer therapeutics.

Loading

Article metrics loading...

/content/journals/cctr/10.2174/1573394714666181022123329
2019-08-01
2025-05-26
Loading full text...

Full text loading...

/content/journals/cctr/10.2174/1573394714666181022123329
Loading

  • Article Type:
    Article Commentary
Keyword(s): Aging; cancer; diabetes; epigenetic programming; metabolite; tumor
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test